Intensity Therapeutics, Inc.

Equities

INTS

US45828J1034

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-08 pm EDT			5-day change	1st Jan Change
0.2902 ^USD	+2.40%		-5.47%	-83.51%

Jun. 30	Intensity Reports Complete Response Rate in Neurological Cancer Models	MT
Jun. 30	Intensity Therapeutics, Inc. Announces Int230-6 Achieves 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors	CI

Intensity Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Published on 03/12/2025 at 19:00

Intensity Therapeutics, Inc. filed its 10-K on Mar 13, 2025 for the period ending Dec 31, 2024. In this report its auditor, EisnerAmper LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about Intensity Therapeutics, Inc.

Intensity Reports Complete Response Rate in Neurological Cancer Models	Jun. 30	MT
Intensity Therapeutics, Inc. Announces Int230-6 Achieves 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors	Jun. 30	CI
Intensity Therapeutics Prices Public Offering Of 6,675,000 Shares At $0.30 Per Share	Jun. 11	RE
Intensity Therapeutics Plans Public Share Offering to Fund Cancer Trial	Jun. 11	MT
Intensity Therapeutics Announces Proposed Public Offering Of Common Stock	Jun. 11	RE
Intensity Therapeutics Announces Patients Receiving INT230-6 Prior To Start Of Standard-Of-Care May Achieve High Levels Of Tumor Necrosis In Ongoing Randomized Controlled Phase 2 Invincible-4 Study	Jun. 11	RE
Intensity Therapeutics, Inc. Announces Patients Receiving Int230-6 Prior to the Start of Standard-Of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 Invincible-4 Study	Jun. 11	CI
Intensity Therapeutics to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy	May. 28	RE
Brookline Capital Downgrades Intensity Therapeutics to Hold From Buy	May. 19	MT
Intensity Therapeutics Q1 Basic EPS USD -0.22	May. 13	RE
Intensity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 13	CI
Intensity Therapeutics, Inc. and the Swiss Group for Clinical Cancer Research Sakk Receive European Medicines Agency Authorization to Initiate Phase 2 Invincible-4 (Sakk/66/22) Study for Int230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France	May. 06	CI
Wall Street Set to Open Lower Friday Amid Slew of Earnings Reports	Apr. 25	MT
Investors Parse Earnings Reports as US Futures Dip in Fridays Premarket	Apr. 25	MT
Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	Mar. 13	CI
Intensity Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	Mar. 12	CI
Intensity Therapeutics Says Stockholder Armistice Capital May Sell 1.24 Million Shares	Dec. 13	MT
Intensity Therapeutics Says Cancer Drug Candidate Shows Benefits in Phase 2 Trial	Dec. 12	MT
Intensity Therapeutics, Inc. and the Swiss Group for Clinical Cancer Research Sakk Present Phase 2 Data in Presurgical Breast Cancer from the Completed Invincible-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, At the 2024 San Antonio Breast Cancer Symposium	Dec. 12	CI
Intensity Therapeutics, Inc. Presents Int230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial	Nov. 18	CI
Earnings Flash (INTS) INTENSITY THERAPEUTICS Reports Q3 Loss $-0.25	Nov. 13	MT
Intensity Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 13	CI
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)	24-10-31	CI
Earnings Flash (INTS) INTENSITY THERAPEUTICS Posts Q2 Loss $-0.36	24-08-08	MT
Intensity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-08	CI

Chart Intensity Therapeutics, Inc.

Duration

Period

INTS: Dynamic Chart

Company Profile

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. The Company is engaged in developing treatments that address both the regional and systemic nature of a patientâs cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead investigational product candidate, INT230-6, is designed for direct intratumoral injection. Its INT230-6 is primarily comprised of three components: cisplatin, vinblastine sulfate and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of Phase III open-label, randomized study testing the superiority of INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, and Phase II/III clinical study in metastatic triple negative breast cancer.

Employees

Sector

Biotechnology & Medical Research

Calendar

Jul. 16 - Annual General Meeting

More about the company